World Journal of Surgical Oncology最新文献

筛选
英文 中文
Efficacy and toxicity of KRASG12C inhibitors in advanced solid tumors: a meta-analysis. KRASG12C 抑制剂在晚期实体瘤中的疗效和毒性:一项荟萃分析。
IF 2.5 3区 医学
World Journal of Surgical Oncology Pub Date : 2024-07-16 DOI: 10.1186/s12957-024-03449-8
Shoutao Dang, Shuyang Zhang, Jingyang Zhao, Wei Li
{"title":"Efficacy and toxicity of KRAS<sup>G12C</sup> inhibitors in advanced solid tumors: a meta-analysis.","authors":"Shoutao Dang, Shuyang Zhang, Jingyang Zhao, Wei Li","doi":"10.1186/s12957-024-03449-8","DOIUrl":"10.1186/s12957-024-03449-8","url":null,"abstract":"<p><strong>Background: </strong>The efficacy and toxicity of KRAS<sup>G12C</sup> inhibitors were evaluated for advanced solid tumors in several studies; however, the results were not fully consistent.</p><p><strong>Methods: </strong>Clinical trials evaluating KRAS<sup>G12C</sup> inhibitors for advanced solid tumors were searched from PubMed, Embase, and Cochrane Library online databases up to 31st December 2023. The characteristics of the studies and the results of objective response rate (ORR), disease control rate (DCR), duration of response (DoR), progression-free survival (PFS) rate, overall survival (OS) rate, and treatment-related adverse events (trAEs) were extracted.</p><p><strong>Results: </strong>Ten studies with 925 heavily pretreated advanced patients harboring KRAS<sup>G12C</sup> mutation were included. For total population, the pooled analysis of ORR was 28.6% (95%CI, 21.2-36.6%), DCR was 85.5% (95%CI, 82.2-88.6%), PFS rate at 6 months (PFS6) was 49.6% (95%CI, 41.4-57.9%), PFS rate at 12 months (PFS12) was 26.7% (95%CI, 19.8-34.1%), OS rates at 6 months (OS6) was 76.2% (95%CI, 68.8-82.9%), OS rates at 12 months (OS12) was 47.8% (95%CI, 38.6-57.0%). The pooled analysis of any grade trAEs was 79.3% (95%CI, 66.2-90.0%) and grade three or more trAEs was 24.4% (95%CI, 16.7-32.9%). The median time to response and DoR results from individual data were 1.39 months (95%CI, 1.37-1.41 months) and 10.54 months (95%CI, 7.72-13.36 months). Sotorasib had significantly lower pooled incidences of any trAEs (OR, 0.07, 95%CI, 0.03-0.14) and grade three or more trAES (OR, 0.34, 95%CI, 0.24-0.49) compared with adagrasib.</p><p><strong>Conclusions: </strong>KRAS<sup>G12C</sup> inhibitors have good ORR, DCR, PFS rate, OS rate, tolerable trAEs, and early response with long duration in advanced solid tumors; however, most of the pooled results were heterogeneous. Sotorasib has shown better safety results.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11251097/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141621076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A study predicting long-term survival capacity in postoperative advanced gastric cancer patients based on MAOA and subcutaneous muscle fat characteristics. 基于 MAOA 和皮下肌肉脂肪特征预测晚期胃癌术后患者长期生存能力的研究。
IF 2.5 3区 医学
World Journal of Surgical Oncology Pub Date : 2024-07-16 DOI: 10.1186/s12957-024-03466-7
Yubo Han, Yaoyuan Chang, Jiaqi Wang, Nanbo Li, Yang Yu, Zhengbo Yang, Weipeng Lv, Wenfei Liu, Jiajun Yin, Ju Wu
{"title":"A study predicting long-term survival capacity in postoperative advanced gastric cancer patients based on MAOA and subcutaneous muscle fat characteristics.","authors":"Yubo Han, Yaoyuan Chang, Jiaqi Wang, Nanbo Li, Yang Yu, Zhengbo Yang, Weipeng Lv, Wenfei Liu, Jiajun Yin, Ju Wu","doi":"10.1186/s12957-024-03466-7","DOIUrl":"10.1186/s12957-024-03466-7","url":null,"abstract":"<p><strong>Background: </strong>The prognosis of advanced gastric cancer (AGC) is relatively poor, and long-term survival depends on timely intervention. Currently, predicting survival rates remains a hot topic. The application of radiomics and immunohistochemistry-related techniques in cancer research is increasingly widespread. However, their integration for predicting long-term survival in AGC patients has not been fully explored.</p><p><strong>Methods: </strong>We Collected 150 patients diagnosed with AGC at the Affiliated Zhongshan Hospital of Dalian University who underwent radical surgery between 2015 and 2019. Following strict inclusion and exclusion criteria, 90 patients were included in the analysis. We Collected postoperative pathological specimens from enrolled patients, analyzed the expression levels of MAOA using immunohistochemical techniques, and quantified these levels as the MAOAHScore. Obtained plain abdominal CT images from patients, delineated the region of interest at the L3 vertebral body level, and extracted radiomics features. Lasso Cox regression was used to select significant features to establish a radionics risk score, convert it into a categorical variable named risk, and use Cox regression to identify independent predictive factors for constructing a clinical prediction model. ROC, DCA, and calibration curves validated the model's performance.</p><p><strong>Results: </strong>The enrolled patients had an average age of 65.71 years, including 70 males and 20 females. Multivariate Cox regression analysis revealed that risk (P = 0.001, HR = 3.303), MAOAHScore (P = 0.043, HR = 2.055), and TNM stage (P = 0.047, HR = 2.273) emerged as independent prognostic risk factors for 3-year overall survival (OS) and The Similar results were found in the analysis of 3-year disease-specific survival (DSS). The nomogram developed could predict 3-year OS and DSS rates, with areas under the ROC curve (AUCs) of 0.81 and 0.797, respectively. Joint calibration and decision curve analyses (DCA) confirmed the nomogram's good predictive performance and clinical utility.</p><p><strong>Conclusion: </strong>Integrating immunohistochemistry and muscle fat features provides a more accurate prediction of long-term survival in gastric cancer patients. This study offers new perspectives and methods for a deeper understanding of survival prediction in AGC.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11251287/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141621074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chemoradiotherapy versus radiotherapy in high risk salivary gland cancer 高风险唾液腺癌的化疗与放疗对比
IF 3.2 3区 医学
World Journal of Surgical Oncology Pub Date : 2024-07-11 DOI: 10.1186/s12957-024-03456-9
Yicheng Shen, Jiebo Shan
{"title":"Chemoradiotherapy versus radiotherapy in high risk salivary gland cancer","authors":"Yicheng Shen, Jiebo Shan","doi":"10.1186/s12957-024-03456-9","DOIUrl":"https://doi.org/10.1186/s12957-024-03456-9","url":null,"abstract":"The aim of this study was to investigate the potential survival benefits associated with chemoradiotherapy (CRT) as opposed to radiotherapy (RT) in patients with resected high-risk salivary gland cancer (SGC), with a specific focus on determining whether these benefits are influenced by the number of high-risk variables. Patients who underwent surgical treatment for high-risk SGC were retrospectively enrolled and categorized into either CRT or RT groups. The impact of adjuvant therapy on locoregional control (LRC) and overall survival (OS) was assessed using a multivariable Cox model. A total of 152 patients were included following propensity score-matching. In comparison to RT, CRT did not demonstrate a significant survival advantage in terms of LRC (p = 0.485, HR: 1.14, 95%CI: 0.36–4.22) and OS (p = 0.367, HR: 0.99, 95%CI: 0.17–3.87) in entire population. But among patients with T3/4 stage, high-grade tumors, and 5 or more positive lymph nodes, the addition of chemotherapy to RT significantly (p = 0.042) correlated with a 15% reduction in the risk of cancer recurrence (95%CI: 4-54%). Conversely, in other subgroups with varying combinations of high-risk variables, CRT did not provide additional survival benefits for LRC and OS compared to RT. Adjuvant chemotherapy may be considered in conjunction with RT specifically in cases where there is a presence of T3/4 stage, high-grade tumors, and 5 or more metastatic lymph nodes in high-risk SGC.","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141586767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Short-term OS as a surrogate endpoint for 5-year OS in nasopharyngeal carcinoma in non-endemic area. 将短期生存期作为非流行区鼻咽癌 5 年生存期的替代终点。
IF 2.5 3区 医学
World Journal of Surgical Oncology Pub Date : 2024-07-11 DOI: 10.1186/s12957-024-03460-z
Ying Guan, Lu Han, Han-Yin Luo, Bin-Bin Yu, Shi-Ting Huang
{"title":"Short-term OS as a surrogate endpoint for 5-year OS in nasopharyngeal carcinoma in non-endemic area.","authors":"Ying Guan, Lu Han, Han-Yin Luo, Bin-Bin Yu, Shi-Ting Huang","doi":"10.1186/s12957-024-03460-z","DOIUrl":"10.1186/s12957-024-03460-z","url":null,"abstract":"<p><strong>Purpose: </strong>To address this evidence gap and validate short-term OS at less than 5 years as a reliable surrogate endpoint for 5-year OS.</p><p><strong>Methods: </strong>We analyzed data from the Surveillance, Epidemiology, and End Results (SEER) database, focusing on non-metastatic NPC patients diagnosed between 2010 and 2015. Patients were categorized into radiotherapy and chemoradiotherapy groups.</p><p><strong>Results: </strong>This retrospective study examined 2,047 non-metastatic NPC patients. Among them, 217 received radiotherapy, and 1,830 received chemoradiotherapy. Our analysis results indicated that the 4-year OS may serve as a reliable surrogate endpoint for patients with AJCC clinical stage I (80 vs. 78%, P = 0.250), regardless of the treatment received. Specifically, in the radiotherapy group, patients with stage I, T0-T1, and N0 NPC showed similar OS rates at 4 and 5 years (83 vs. 82%, P = 1.000; 78 vs. 76%, P = 0.250; 78 vs. 77%, P = 0.500, respectively). Similarly, patients with stage II-IV, T2-T4, and N1-3 NPC showed no significant difference in OS rates between 3 and 5 years (57 vs. 51%, P = 0.063; 52 vs. 46%, P = 0.250; 54 vs. 46%, P = 0.125, respectively) in the radiotherapy group. In the chemoradiotherapy group, only the 3-year OS rate did not significantly differ from that at 5 years in stage I patients (79vs. 72%, P = 0.063).</p><p><strong>Conclusions: </strong>Our study suggests that short-term surrogate endpoints may be valuable for evaluating 5-year OS outcomes in NPC patients in non-endemic areas.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11238357/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141580989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Malignant solitary fibrous tumor of the kidney with IGF2 secretion and without hypoglycemia. 肾脏恶性单发纤维瘤伴有 IGF2 分泌,但无低血糖症。
IF 2.5 3区 医学
World Journal of Surgical Oncology Pub Date : 2024-07-09 DOI: 10.1186/s12957-024-03342-4
Luting Zhou, Yang Liu, Teng Xu, Lei Dong, Xiaoqun Yang, Chaofu Wang
{"title":"Malignant solitary fibrous tumor of the kidney with IGF2 secretion and without hypoglycemia.","authors":"Luting Zhou, Yang Liu, Teng Xu, Lei Dong, Xiaoqun Yang, Chaofu Wang","doi":"10.1186/s12957-024-03342-4","DOIUrl":"10.1186/s12957-024-03342-4","url":null,"abstract":"<p><strong>Background: </strong>Solitary fibrous tumor (SFT) is a rare fibroblastic mesenchymal tumor that mostly involves the pleura and infrequently involves extra-pleural sites. De novo SFT of the kidney is uncommon, and malignant SFT is extremely rare.</p><p><strong>Case presentation: </strong>We report a case of a 51-year-old man with a large malignant SFT in the left kidney. Pathological examination confirmed the diagnosis of SFT based on typical morphology, nuclear STAT6 expression, and NAB2-STAT6 gene fusion. The malignant subtype was determined by a large tumor size (≥ 15 cm) and high mitotic counts (8/10 high-power fields). KRAS mutation was identified by DNA sequencing. Insulin-like growth factor 2 (IGF2) was diffusely and strongly expressed in tumor cells, however, hypoglycemia was not observed. Hyperglycemia and high adrenocorticotropic hormone (ACTH) concentration were observed one month after surgery. Hormone measurements revealed normal blood cortisol and aldosterone levels, and increased urinary free cortisol level. A pituitary microadenoma was identified using brain magnetic resonance imaging, which may be responsible for the promotion of hyperglycemia.</p><p><strong>Conclusions: </strong>We report a case of renal malignant SFT with a KRAS mutation, which was previously unreported in SFT and may be associated with its malignant behavior. Additionally, we emphasize that malignant SFT commonly causes severe hypoglycemia due to the production of IGF2. However, this effect may be masked by the presence of other lesions that promote hyperglycemia. Therefore, when encountering a malignant SFT with diffuse and strong IGF2 expression and without hypoglycemia, other lesions promoting hyperglycemia need to be ruled out.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11234528/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141564540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeted axillary dissection reduces residual nodal disease in clinically node- positive breast cancer after neoadjuvant chemotherapy. 靶向腋窝切除术可减少新辅助化疗后临床结节阳性乳腺癌的残余结节病。
IF 2.5 3区 医学
World Journal of Surgical Oncology Pub Date : 2024-07-06 DOI: 10.1186/s12957-024-03413-6
Neslihan Cabıoğlu, Hasan Karanlık, Ravza Yılmaz, Selman Emiroğlu, Mustafa Tükenmez, Süleyman Bademler, Duygu Has Şimşek, Tarık Recep Kantarcı, İnci Kızıldağ Yirgin, Aysel Bayram, Memduh Dursun
{"title":"Targeted axillary dissection reduces residual nodal disease in clinically node- positive breast cancer after neoadjuvant chemotherapy.","authors":"Neslihan Cabıoğlu, Hasan Karanlık, Ravza Yılmaz, Selman Emiroğlu, Mustafa Tükenmez, Süleyman Bademler, Duygu Has Şimşek, Tarık Recep Kantarcı, İnci Kızıldağ Yirgin, Aysel Bayram, Memduh Dursun","doi":"10.1186/s12957-024-03413-6","DOIUrl":"10.1186/s12957-024-03413-6","url":null,"abstract":"<p><strong>Background: </strong>Any advantage of performing targeted axillary dissection (TAD) compared to sentinel lymph node (SLN) biopsy (SLNB) is under debate in clinically node-positive (cN+) patients diagnosed with breast cancer. Our objective was to assess the feasibility of the removal of the clipped node (RCN) with TAD or without imaging-guided localisation by SLNB to reduce the residual axillary disease in completion axillary lymph node dissection (cALND) in cN+ breast cancer.</p><p><strong>Methods: </strong>A combined analysis of two prospective cohorts, including 253 patients who underwent SLNB with/without TAD and with/without ALND following NAC, was performed. Finally, 222 patients (cT1-3N1/ycN0M0) with a clipped lymph node that was radiologically visible were analyzed.</p><p><strong>Results: </strong>Overall, the clipped node was successfully identified in 246 patients (97.2%) by imaging. Of 222 patients, the clipped lymph nodes were non-SLNs in 44 patients (19.8%). Of patients in cohort B (n=129) with TAD, the clipped node was successfully removed by preoperative image-guided localisation, or the clipped lymph node was removed as the SLN as detected on preoperative SPECT-CT. Among patients with ypSLN(+) (n=109), no significant difference was found in non-SLN positivity at cALND between patients with TAD and RCN (41.7% vs. 46.9%, p=0.581). In the subgroup with TAD with axillary lymph node dissection (ALND; n=60), however, patients with a lymph node (LN) ratio (LNR) less than 50% and one metastatic LN in the TAD specimen were found to have significantly decreased non-SLN positivity compared to others (27.6% vs. 54.8%, p=0.032, and 22.2% vs. 50%, p=0.046).</p><p><strong>Conclusions: </strong>TAD by imaging-guided localisation is feasible with excellent identification rates of the clipped node. This approach has also been found to reduce the additional non-SLN positivity rate to encourage omitting ALND in patients with a low metastatic burden undergoing TAD.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11227135/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141545351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Population-Specific gene expression profiles in prostate cancer: insights from Weighted Gene Co-expression Network Analysis (WGCNA). 前列腺癌人群特异性基因表达谱:加权基因共表达网络分析(WGCNA)的启示
IF 2.5 3区 医学
World Journal of Surgical Oncology Pub Date : 2024-07-05 DOI: 10.1186/s12957-024-03459-6
Laleh Manouchehri, Zahra Zinati, Leyla Nazari
{"title":"Population-Specific gene expression profiles in prostate cancer: insights from Weighted Gene Co-expression Network Analysis (WGCNA).","authors":"Laleh Manouchehri, Zahra Zinati, Leyla Nazari","doi":"10.1186/s12957-024-03459-6","DOIUrl":"10.1186/s12957-024-03459-6","url":null,"abstract":"<p><p>This study investigates the genetic factors contributing to the disparity in prostate cancer incidence and progression among African American men (AAM) compared to European American men (EAM). The research focuses on employing Weighted Gene Co-expression Network Analysis (WGCNA) on public microarray data obtained from prostate cancer patients. The study employed WGCNA to identify clusters of genes with correlated expression patterns, which were then analyzed for their connection to population backgrounds. Additionally, pathway enrichment analysis was conducted to understand the significance of the identified gene modules in prostate cancer pathways. The Least Absolute Shrinkage and Selection Operator (LASSO) and Correlation-based Feature Selection (CFS) methods were utilized for selection of biomarker genes. The results revealed 353 differentially expressed genes (DEGs) between AAM and EAM. Six significant gene expression modules were identified through WGCNA, showing varying degrees of correlation with prostate cancer. LASSO and CFS methods pinpointed critical genes, as well as six common genes between both approaches, which are indicative of their vital role in the disease. The XGBoost classifier validated these findings, achieving satisfactory prediction accuracy. Genes such as APRT, CCL2, BEX2, MGC26963, and PLAU were identified as key genes significantly associated with cancer progression. In conclusion, the research underlines the importance of incorporating AAM and EAM population diversity in genomic studies, particularly in cancer research. In addition, the study highlights the effectiveness of integrating machine learning techniques with gene expression analysis as a robust methodology for identifying critical genes in cancer research.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11225268/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141538739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management strategy for children with ovarian immature teratoma: results from a tertiary pediatric oncology center. 卵巢未成熟畸胎瘤患儿的管理策略:一家三级儿科肿瘤中心的研究结果。
IF 2.5 3区 医学
World Journal of Surgical Oncology Pub Date : 2024-07-04 DOI: 10.1186/s12957-024-03452-z
Gehad Ahmed, Sahar Ahmed Khalil, Maged Elshafiey, Nihal Abdelfattah, Mohamed Eid, Al-Shaimaa Zakaria, Madeeha Elwakeel, Ahmed Elgendy
{"title":"Management strategy for children with ovarian immature teratoma: results from a tertiary pediatric oncology center.","authors":"Gehad Ahmed, Sahar Ahmed Khalil, Maged Elshafiey, Nihal Abdelfattah, Mohamed Eid, Al-Shaimaa Zakaria, Madeeha Elwakeel, Ahmed Elgendy","doi":"10.1186/s12957-024-03452-z","DOIUrl":"10.1186/s12957-024-03452-z","url":null,"abstract":"<p><strong>Objectives: </strong>We present an Egyptian study on pediatric ovarian immature teratomas (ITs), aiming to clarify our treatment strategy selection.</p><p><strong>Methods: </strong>A retrospective review of all children with pure ovarian ITs who were treated at our institution between 2008 and 2023. The analysis included clinical characteristics, tumor staging according to Children's Oncology Group (COG), grading based on the Norris system, management, and outcomes.</p><p><strong>Results: </strong>Thirty-two patients were included, with a median age of 9 years. All patients underwent primary surgery. Unilateral salpingo-oophorectomy was performed in 31 patients. Surgical staging was completed in all patients. Based on COG staging, there were 28 patients (87.5%) stage I, 1 (3%) stage II, and 3 (9.5%) stage III. According to Norris classification, 16 patients (50%) were classified as grade I, 9 (28%) grade II, and 7 (22%) grade III. All patients in stage I were treated using surgery-alone approach, whereas the remaining four (12.5%) received adjuvant chemotherapy. Five patients in stage I had gliomatosis peritonei (GP), and none of them underwent extensive surgery. At a median follow-up of 86 months, two patients had events. The first patient (stage III/grade I) developed IT relapse on the operative bed, and the second (stage I/grade I) had a metachronous IT on the contralateral ovary. Both patients were successfully managed with surgery followed by second-line chemotherapy. Five-year overall survival and event-free survival for all patients were 100% and 93.4%, respectively.</p><p><strong>Conclusions: </strong>Surgery-alone strategy with close follow-up achieves excellent outcomes for localized ovarian ITs in children, irrespective of the Norris grading or the presence of GP. However, adjuvant chemotherapy is questionable for patients with incompletely resected or locally advanced tumors, and its role requires further evaluation through prospective multicentric studies with a larger sample size.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11223275/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141535469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The survival prediction of advanced colorectal cancer received neoadjuvant therapy-a study of SEER database. 晚期结直肠癌接受新辅助治疗后的生存预测--一项 SEER 数据库研究。
IF 2.5 3区 医学
World Journal of Surgical Oncology Pub Date : 2024-07-01 DOI: 10.1186/s12957-024-03458-7
Zhuo Han, Haicheng Yang, Qing Qiao, Tao Wu, Xianli He, Nan Wang
{"title":"The survival prediction of advanced colorectal cancer received neoadjuvant therapy-a study of SEER database.","authors":"Zhuo Han, Haicheng Yang, Qing Qiao, Tao Wu, Xianli He, Nan Wang","doi":"10.1186/s12957-024-03458-7","DOIUrl":"10.1186/s12957-024-03458-7","url":null,"abstract":"<p><strong>Purpose: </strong>The aim of study was to screen factors associated with the overall survival of colorectal cancer patients with lymph nodes metastasis who received neoadjuvant therapy and construct a nomogram model.</p><p><strong>Methods: </strong>All enrolled subjects of the SEER database were randomly assigned to the training and testing group in a ratio of 3:2. The patients of Tangdu Hospital were seemed as validation group. Univariate cox regression analysis, lasso regression and random forest survival were used to screen variables related to the survival of advanced CRC patients received neoadjuvant therapy in the training group. Area under curves were adopted to evaluate the 1,3,5-year prediction value of the optimal model in three cohorts. Calibration curves were drawn to observe the prediction accuracy of the nomogram model. Decision curve analysis was used to assess the potential clinical value of the nomogram model.</p><p><strong>Results: </strong>A total of 1833 subjects were enrolled in this study. After random allocation, 1055 cases of the SEER database served as the training group, 704 cases as the testing group and 74 patients from our center as the external validation group. Variables were screened by univariate cox regression used to construct a nomogram survival prediction model, including M, age, chemotherapy, CEA, perineural invasion, tumor size, LODDS, liver metastasis and radiation. The AUCs of the model for predicting 1-year OS in the training group, testing and validation group were 0.765 (0.703,0.827), 0.772 (0.697,0.847) and 0.742 (0.601,0.883), predicting 3-year OS were 0.761 (0.725,0.780), 0.742 (0.699,0.785), 0.733 (0.560,0.905) and 5-year OS were 0.742 (0.711,0.773), 0.746 (0.709,0.783), 0.838 (0.670,0.980), respectively. The calibration curves showed the difference between prediction probability of the model and the actual survival was not significant in three cohorts and the decision curve analysis revealed the practice clinical application value. And the prediction value of model was better for young CRC than older CRC patients.</p><p><strong>Conclusion: </strong>A nomogram model including LODDS for the prognosis of advanced CRC received neoadjuvant therapy was constructed and verified based on the SEER database and single center practice. The accuracy and potential clinical application value of the model performed well, and the model had better predictive value for EOCRC than LOCRC.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11218294/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141477536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Venous resection increases risk of chyle leak after total pancreatectomy for pancreatic tumors. 静脉切除会增加胰腺肿瘤全胰切除术后胰液漏的风险。
IF 2.5 3区 医学
World Journal of Surgical Oncology Pub Date : 2024-06-28 DOI: 10.1186/s12957-024-03451-0
Tianyu Li, Chen Lin, Bangbo Zhao, Zeru Li, Yutong Zhao, Xianlin Han, Menghua Dai, Junchao Guo, Weibin Wang
{"title":"Venous resection increases risk of chyle leak after total pancreatectomy for pancreatic tumors.","authors":"Tianyu Li, Chen Lin, Bangbo Zhao, Zeru Li, Yutong Zhao, Xianlin Han, Menghua Dai, Junchao Guo, Weibin Wang","doi":"10.1186/s12957-024-03451-0","DOIUrl":"https://doi.org/10.1186/s12957-024-03451-0","url":null,"abstract":"<p><strong>Background: </strong>Existing research on chyle leak (CL) after pancreatic surgery is mostly focused on pancreaticoduodenectomy and lacks investigation on total pancreatectomy (TP). This study aimed to explore potential risk factors of CL and develop a predictive model for patients with pancreatic tumor undergoing TP.</p><p><strong>Methods: </strong>This retrospective study enrolled 90 consecutive patients undergoing TP from January 2015 to December 2023 at Peking Union Medical College Hospital. According to the inclusion criteria, 79 patients were finally included in the following analysis. The LASSO regression and multivariate logistic regression analysis were performed to identify risk factors associated with CL and construct a predictive nomogram. Then, the ROC analysis, calibration curve, decision curve analysis (DCA), and clinical impact curve (CIC) were performed to assess its discrimination, accuracy, and efficacy. Due to the small sample size, we adopted the bootstrap resampling method with 500 repetitions for validation. Lastly, we plotted and analyzed the trend of postoperative drainage volume in CL patients.</p><p><strong>Results: </strong>We revealed that venous resection (OR = 4.352, 95%CI 1.404-14.04, P = 0.011) was an independent risk factor for CL after TP. Prolonged operation time (OR = 1.473, 95%CI 1.015-2.237, P = 0.052) was also associated with an increased incidence of CL. We included these two factors in our prediction model. The area under the curve (AUC) was 0.752 (95%CI 0.622-0.874) after bootstrap. The calibration curve, DCA and CIC showed great accuracy and clinical benefit of our nomogram. In patients with CL, the mean drainage volume was significantly higher in venous resection group and grade B CL group.</p><p><strong>Conclusion: </strong>Venous resection was an independent risk factor for chyle leak after TP. Patients undergoing vascular resection during TP should be alert for the occurrence of CL after surgery. We then constructed a nomogram consisted of venous resection and operation time to predict the odds of CL in patients undergoing TP.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11214213/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141471117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信